BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34522456)

  • 1. Comprehensive identification of
    Gu W; Yang J; Wang Y; Xu J; Wang X; Du F; Hu X; Guo H; Song C; Tao R; Zhang X
    Am J Cancer Res; 2021; 11(8):3893-3906. PubMed ID: 34522456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
    Katoh M
    Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
    Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
    Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
    Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients.
    Sun Y; Li G; Zhu W; He Q; Liu Y; Chen X; Liu J; Lin J; Han-Zhang H; Yang Z; Lizaso A; Xiang J; Mao X; Liu H; Gao Y
    Ann Transl Med; 2020 Oct; 8(20):1290. PubMed ID: 33209870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.
    Zhou Z; Liu Z; Ou Q; Wu X; Wang X; Shao Y; Liu H; Yang Y
    Cancer Biol Med; 2021 Mar; 18(2):490-501. PubMed ID: 33710807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
    Helsten T; Elkin S; Arthur E; Tomson BN; Carter J; Kurzrock R
    Clin Cancer Res; 2016 Jan; 22(1):259-67. PubMed ID: 26373574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
    Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
    Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.
    Lazo De La Vega L; Comeau H; Sallan S; Al-Ibraheemi A; Gupta H; Li YY; Tsai HK; Kang W; Ward A; Church AJ; Kim A; Pinto NR; Macy ME; Maese LD; Sabnis AJ; Cherniack AD; Lindeman NI; Anderson ME; Cooney TM; Yeo KK; Reaman GH; DuBois SG; Collins NB; Johnson BE; Janeway KA; Forrest SJ
    JCO Precis Oncol; 2022 Nov; 6():e2200390. PubMed ID: 36446043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
    Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
    ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
    Chae YK; Hong F; Vaklavas C; Cheng HH; Hammerman P; Mitchell EP; Zwiebel JA; Ivy SP; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Mansfield A; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    J Clin Oncol; 2020 Jul; 38(21):2407-2417. PubMed ID: 32463741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors.
    Granberg KJ; Raita A; Lehtinen B; Tiihonen AM; Kesseli J; Annala M; Rodriguez-Martinez A; Nordfors K; Zhang W; Visakorpi T; Nykter M; Haapasalo H
    Histol Histopathol; 2020 Jul; 35(7):673-680. PubMed ID: 31660579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
    Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
    Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.
    Theelen WS; Mittempergher L; Willems SM; Bosma AJ; Peters DD; van der Noort V; Japenga EJ; Peeters T; Koole K; Šuštić T; Blaauwgeers JL; van Noesel CJ; Bernards R; van den Heuvel MM
    J Pathol Clin Res; 2016 Oct; 2(4):223-233. PubMed ID: 27785367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas.
    Lehtinen B; Raita A; Kesseli J; Annala M; Nordfors K; Yli-Harja O; Zhang W; Visakorpi T; Nykter M; Haapasalo H; Granberg KJ
    BMC Cancer; 2017 May; 17(1):310. PubMed ID: 28468611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
    Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
    Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR- gene family alterations in low-grade neuroepithelial tumors.
    Bale TA
    Acta Neuropathol Commun; 2020 Feb; 8(1):21. PubMed ID: 32085805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
    Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.